# EDGAR Filing Document

**Accession Number:** 0001661998
**File Stem:** 0001193125-26-272562
**Filing Date:** 2026-6
**Character Count:** 6664
**Document Hash:** 6b592f65297274bba15efc1cfe4dd5cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-272562.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001193125-26-272562

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260612

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260616

**DATE AS OF CHANGE**: 20260616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q32 Bio Inc.
- **CENTRAL INDEX KEY:** 0001661998
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473468154
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38433
- **FILM NUMBER:** 261094511

**BUSINESS ADDRESS:**
- **STREET 1:** 830 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 781-999-0232

**MAIL ADDRESS:**
- **STREET 1:** 830 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Homology Medicines, Inc.
- **DATE OF NAME CHANGE:** 20151228

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 12, 2026

## Q32 Bio Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38433** | **47-3468154** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **830 Winter Street** |  |
| **Waltham, Massachusetts** | **02451** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: 781 999-0232

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common stock, par value $0.0001 per share | QTTB | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

During the 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Q32 Bio Inc. (the "Company"), the Company's stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2026 in connection with the Annual Meeting. Represented in person or by proxy at the Annual Meeting were 11,833,800 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), out of 15,629,463 shares of Common Stock entitled to vote at the Annual Meeting, or 75.71% of the total number of shares of Common Stock outstanding as of April 15, 2026, the record date. The final voting results of the matters submitted to the stockholders' vote are set forth below.

<u>Proposal No. 1 - Election of Class</u> <u>II Directors:</u>

The stockholders of the Company elected Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D., as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. The results of the stockholders' vote with respect to the election of the Class II directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Name | Votes For | Votes Withheld | Broker Non-Votes |
|  Kathleen LaPorte | 7187421 | 1428633 | 3217746 |
|  Jodie Morrison | 8591626 | 24428 | 3217746 |
|  Arthur Tzianabos, Ph.D. | 8310837 | 305217 | 3217746 |

---

<u>Proposal No. 2 - Ratification of the Appointment of Ernst</u> <u>& Young LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December</u> <u>31, 2026:</u>

The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 11821046 | 7909 | 4845 |  |

---

<u>Proposal No. 3 - Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers:</u>

The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The results of the stockholders' vote with respect to such approval were as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 8072067 | 400598 | 143389 | 3217746 |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **Q32 BIO INC.** |
| Date: June 16, 2026 | By: | /s/ Jodie Morrison |
|  | Name: | Jodie Morrison |
|  | Title: | Chief Executive Officer |

---